Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abbisko Cayman Limited ( (HK:2256) ) has shared an update.
Abbisko Cayman Limited reported that shareholders approved all resolutions at its annual general meeting held on May 20, 2026, including the adoption of audited financial statements for 2025, re-election of certain independent non-executive directors, reappointment of Ernst & Young as auditor, and authorization for the board to set directors’ and auditor’s remuneration. Investors also renewed general mandates for the board to issue and repurchase shares, allowed an extension of the issuance mandate via repurchased shares, and backed amendments to the company’s memorandum and articles of association, enhancing capital management flexibility and updating its governance framework.
The repurchase mandate permits the company to either cancel repurchased shares or hold them as treasury shares, which will carry no voting rights while registered in the company’s name. This structure provides Abbisko greater agility in managing its capital base and potential future fundraising, while the strong support for corporate governance changes signals shareholder confidence in the board’s strategic direction and oversight.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$27.10 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a Hong Kong-listed company incorporated in the Cayman Islands, operating within the broader biopharmaceutical and healthcare sector. The company focuses on developing and commercializing innovative therapies, and is governed by a board of directors and independent non-executive directors in line with Hong Kong capital market standards.
Average Trading Volume: 1,926,074
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.44B
For detailed information about 2256 stock, go to TipRanks’ Stock Analysis page.